Efficiency of NHEJ-CRISPR/Cas9 and Cre-LoxP Engineered Recombinant Turkey Herpesvirus Expressing Pasteurella multocida OmpH Protein for Fowl Cholera Prevention in Ducks
Author:
Apinda Nisachon1, Yao Yongxiu2ORCID, Zhang Yaoyao2, Muenthaisong Anucha13ORCID, Sangkakam Kanokwan1, Nambooppha Boondarika1ORCID, Rittipornlertrak Amarin1, Koonyosying Pongpisid13ORCID, Nair Venugopal245ORCID, Sthitmatee Nattawooti1ORCID
Affiliation:
1. Laboratory of Veterinary Vaccine and Biological Products, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50200, Thailand 2. The Pirbright Institute, Woking GU24 0NF, UK 3. Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand 4. Jenner Institute, University of Oxford, Oxford OX1 2JD, UK 5. Department of Biology, University of Oxford, Oxford OX1 3SZ, UK
Abstract
Fowl cholera is caused by the bacterium Pasteurella multocida, a highly transmissible avian ailment with significant global implications, leading to substantial economic repercussions. The control of fowl cholera outbreaks primarily relies on vaccination using traditional vaccines that are still in use today despite their many limitations. In this research, we describe the development of a genetically engineered herpesvirus of turkeys (HVT) that carries the OmpH gene from P. multocida integrated into UL 45/46 intergenic region using CRISPR/Cas9-NHEJ and Cre-Lox system editing. The integration and expression of the foreign cassettes were confirmed using polymerase chain reaction (PCR), indirect immunofluorescence assays, and Western blot assays. The novel recombinant virus (rHVT-OmpH) demonstrated stable integration of the OmpH gene even after 15 consecutive in vitro passages, along with similar in vitro growth kinetics as the parent HVT virus. The protective efficacy of the rHVT-OmpH vaccine was evaluated in vaccinated ducks by examining the levels of P. multocida OmpH-specific antibodies in serum samples using ELISA. Groups of ducks that received the rHVT-OmpH vaccine or the rOmpH protein with Montanide™ (SEPPIC, Paris, France) adjuvant exhibited high levels of antibodies, in contrast to the negative control groups that received the parental HVT or PBS. The recombinant rHVT-OmpH vaccine also provided complete protection against exposure to virulent P. multocida X-73 seven days post-vaccination. This outcome not only demonstrates that the HVT vector possesses many characteristics of an ideal recombinant viral vaccine vector for protecting non-chicken hosts, such as ducks, but also represents significant research progress in identifying a modern, effective vaccine candidate for combatting ancient infectious diseases.
Funder
the National Research Council of Thailand the Biotechnology and Biological Sciences Research Council
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference37 articles.
1. Pasteurella multocida: Diseases and pathogenesis;Wilkie;Pasteurella Multocida,2012 2. Epidemiological prevalence of Pasteurella multocida in ducks;Eldin;Jpn. J. Vet. Res.,2016 3. Pasteurella multocida pathogenesis: 125 years after Pasteur;Harper;FEMS Microbiol. Lett.,2006 4. Oslan, S.N.H., Tan, J.S., Yusoff, A.H., Sulaiman, A.Z., Awang, M.A., Lazim, A.M., Lim, S.J., Oslan, S.N., Saad, M.Z., and Ariff, A.B. (2022). Pasteurellosis Vaccine Commercialization: Physiochemical Factors for Optimum Production. Processes, 10. 5. Pasteurella multocida Vaccine Candidates: A Systematic Review;Mostaan;Avicenna J. Med. Biotechnol.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|